The Nasdaq Stock Market opens in less than one hour and Moderna’s premarket value is already 3.96% down.

Last session, the Nasdaq Stock Market ended with Moderna falling 8.98% to $125.88. The Nasdaq Stock Market jumped 0.51% to $12,807.90, after two consecutive sessions in a row of losses, on what was a somewhat positive trend trading session.

Moderna’s last close was $138.30, 41.80% below its 52-week high of $178.50.

Moderna’s Sales

Moderna’s sales growth is 1841.7% for the present quarter and 19117.5% for the next. The company’s growth estimates for the present quarter is a negative 2.7% and positive 660% for the next.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $125.88 at 09:27 EST, way below its 52-week high of $178.50 and way above its 52-week low of $17.68.

Moderna’s Moving Average

Moderna’s worth is higher than its 50-day moving average of $116.47 and way above its 200-day moving average of $80.87.

Previous days news about Moderna

Philippines to start vaccine talks with Moderna by year-end: CNN. According to Bloomberg Quint on Mon Dec 21, "The Philippines will start talks with Moderna Inc. on or before Dec. 30 to secure supply of the company’s coronavirus vaccine, Foreign Affairs Secretary Teodoro Locsin said Monday.", ""Moderna is interested in giving an allocation," he said in a live-streamed interview with CNN Philippines, citing Philippine ambassador to the U.S. Jose Manuel Romualdez."

Moderna, biontech post worst day for vaccine stocks in a month. According to Bloomberg Quint on Tue Dec 22, "Moderna, BioNTech and Pfizer have each traded off their highs since their vaccines received regulatory clearance.", "Tuesday’s slide puts a small dent in a rally that has pushed Moderna’s shares to jump more than sixfold so far this year while BioNTech has nearly tripled in value."

LEAVE A REPLY

Please enter your comment!
Please enter your name here